Class I and IIa Histone Deacetylases Have Opposite Effects on Sclerostin Gene Regulation
暂无分享,去创建一个
[1] E. Thomas,et al. Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors , 2014, Pharmaceuticals.
[2] Heather L. Plasterer,et al. Rationale for the Development of 2-Aminobenzamide Histone Deacetylase Inhibitors as Therapeutics for Friedreich Ataxia , 2012, Journal of child neurology.
[3] Jennifer J Westendorf,et al. Histone deacetylases in skeletal development and bone mass maintenance. , 2011, Gene.
[4] R. Gopalakrishnan,et al. HDAC3 and HDAC7 Have Opposite Effects on Osteoclast Differentiation* , 2011, The Journal of Biological Chemistry.
[5] E. Posvar,et al. Single‐dose, placebo‐controlled, randomized study of AMG 785, a sclerostin monoclonal antibody , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[6] A. Younes,et al. The class‐I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6‐independent mechanism , 2010, British journal of haematology.
[7] E. Verdin,et al. Regulatory signal transduction pathways for class IIa histone deacetylases. , 2010, Current opinion in pharmacology.
[8] C. Löwik,et al. Sclerostin: Current Knowledge and Future Perspectives , 2010, Calcified Tissue International.
[9] Xiang Xu,et al. HDAC2 Promotes eIF4E Sumoylation and Activates mRNA Translation Gene Specifically* , 2010, The Journal of Biological Chemistry.
[10] O. Leupin,et al. Does osteocytic SOST suppression mediate PTH bone anabolism? , 2010, Trends in Endocrinology & Metabolism.
[11] James E. Bradner,et al. Chemical Phylogenetics of Histone Deacetylases , 2010, Nature chemical biology.
[12] W. Liu,et al. A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. , 2009, The Journal of clinical investigation.
[13] Jong-Ho Lee,et al. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL. , 2009, European journal of pharmacology.
[14] S. Altamura,et al. Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy. , 2009, Journal of medicinal chemistry.
[15] Yurii S. Aulchenko,et al. Twenty bone mineral density loci identified by large-scale meta-analysis of genome-wide association studies , 2009, Nature Genetics.
[16] A. Lassar,et al. Parathyroid Hormone-Related Peptide Represses Chondrocyte Hypertrophy through a Protein Phosphatase 2A/Histone Deacetylase 4/MEF2 Pathway , 2009, Molecular and Cellular Biology.
[17] M. Mann,et al. Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions , 2009, Science.
[18] G. Loots,et al. Parathyroid Hormone (PTH)–Induced Bone Gain Is Blunted in SOST Overexpressing and Deficient Mice , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[19] Florian Diehl,et al. HDAC5 is a repressor of angiogenesis and determines the angiogenic gene expression pattern of endothelial cells. , 2009, Blood.
[20] Minoru Yoshida,et al. 14-3-3 regulates the nuclear import of class IIa histone deacetylases. , 2008, Biochemical and biophysical research communications.
[21] M. Mann,et al. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.
[22] N. Bertos,et al. Histone deacetylases as transducers and targets of nuclear signaling , 2008, Journal of cellular biochemistry.
[23] P. Kostenuik,et al. Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[24] A. Kalita,et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo , 2008, Molecular Cancer Therapeutics.
[25] P. Finn,et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. , 2008, The Biochemical journal.
[26] F. Natt,et al. Control of the SOST Bone Enhancer by PTH Using MEF2 Transcription Factors , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[27] E. Olson,et al. MEF2: a central regulator of diverse developmental programs , 2007, Development.
[28] Yong-Jun Kwon,et al. High-Content Classification of Nucleocytoplasmic Import or Export Inhibitors , 2007, Journal of biomolecular screening.
[29] W. Link,et al. An HTS approach to screen for antagonists of the nuclear export machinery using high content cell-based assays. , 2007, Assay and drug development technologies.
[30] Mark L. Johnson,et al. The Wnt signaling pathway and bone metabolism , 2007, Current opinion in rheumatology.
[31] G. Karsenty,et al. In vivo analysis of Wnt signaling in bone. , 2007, Endocrinology.
[32] H. Ryoo,et al. Trichostatin A-mediated upregulation of p21WAF1 contributes to osteoclast apoptosis , 2007, Experimental & Molecular Medicine.
[33] John McAnally,et al. MEF2C transcription factor controls chondrocyte hypertrophy and bone development. , 2007, Developmental cell.
[34] Minghong Xu,et al. Histone Deacetylase 3 Interacts with and Deacetylates Myocyte Enhancer Factor 2 , 2006, Molecular and Cellular Biology.
[35] D. Trouche,et al. Cleavage and Cytoplasmic Relocalization of Histone Deacetylase 3 Are Important for Apoptosis Progression , 2006, Molecular and Cellular Biology.
[36] L. Laimins,et al. Histone deacetylase 3 localizes to the plasma membrane and is a substrate of Src , 2006, Oncogene.
[37] P. Chiao,et al. Regulation of Nuclear Translocation of HDAC3 by IκBα Is Required for Tumor Necrosis Factor Inhibition of Peroxisome Proliferator-activated Receptor γ Function* , 2006, Journal of Biological Chemistry.
[38] J. Westendorf,et al. Histone Deacetylase Inhibitors Promote Osteoblast Maturation , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[39] R. Jilka,et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. , 2005, Endocrinology.
[40] T. Hotokebuchi,et al. Inhibition of Histone Deacetylase Suppresses Osteoclastogenesis and Bone Destruction by Inducing IFN-β Production1 , 2005, The Journal of Immunology.
[41] M. Kneissel,et al. SOST is a target gene for PTH in bone. , 2005, Bone.
[42] Bart O. Williams,et al. Essential Role of β-Catenin in Postnatal Bone Acquisition* , 2005, Journal of Biological Chemistry.
[43] Hans Clevers,et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. , 2005, Developmental cell.
[44] Zhenguo Wu,et al. Myocyte Enhancer Factor 2 Acetylation by p300 Enhances Its DNA Binding Activity, Transcriptional Activity, and Myogenic Differentiation , 2005, Molecular and Cellular Biology.
[45] D. Ovcharenko,et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. , 2005, Genome research.
[46] Xiang-Jiao Yang,et al. Association with Class IIa Histone Deacetylases Upregulates the Sumoylation of MEF2 Transcription Factors , 2005, Molecular and Cellular Biology.
[47] E. Olson,et al. Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. , 2005, The Journal of clinical investigation.
[48] B. Harrison,et al. The CRM1 Nuclear Export Receptor Controls Pathological Cardiac Gene Expression , 2004, Molecular and Cellular Biology.
[49] John M. Shelton,et al. Histone Deacetylase 4 Controls Chondrocyte Hypertrophy during Skeletogenesis , 2004, Cell.
[50] John A Latham,et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist , 2003, The EMBO journal.
[51] A. Kukita,et al. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. , 2003, Blood.
[52] Hui Li,et al. SMRTe Inhibits MEF2C Transcriptional Activation by Targeting HDAC4 and 5 to Nuclear Domains* , 2001, The Journal of Biological Chemistry.
[53] E. Olson,et al. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation , 2000, Nature.
[54] M. Yanagida,et al. Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1. , 1998, Experimental cell research.
[55] J. Mellors,et al. INHIBITORS OF HISTONE DEACETYLASES : CORRELATION BETWEEN ISOFORM SPECIFICITY AND REACTIVATION OF HIV-1 FROM LATENTLY INFECTED CELLS * , 2011 .
[56] H. Ryoo,et al. Modulation of the resorption and osteoconductivity of alpha-calcium sulfate by histone deacetylase inhibitors. , 2010, Biomaterials.
[57] E. Olson,et al. The many roles of histone deacetylases in development and physiology: implications for disease and therapy , 2009, Nature Reviews Genetics.
[58] 中村 隆弘. Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-β production , 2005 .
[59] E. Olson,et al. MEF2: a calcium-dependent regulator of cell division, differentiation and death. , 2002, Trends in biochemical sciences.
[60] David D. McDonald,et al. Programs , 1984, CL.